2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4499 Outcomes following CD19-directed CAR T-cell therapy in pediatric Burkitt leukemia and lymphoma: A multicenter real-world study

Farhaz Shaikh, BA, Anya Lia Eden Reinin Platt, MD2, Catherine Aftandilian, MD3, Stacy Cooper I, MD4, Vanessa A. Fabrizio, MD, MS5, Adam Lamble, MD6, Adam Olshen, PhD7, Troy C. Quigg, DO8, Liora Schultz9, Stephanie Thomas, BC-RN10, Randy M. Windreich, M.D.11, Elliot Stieglitz, MD12
1 University of California, San Francisco, San Francisco, California, United States
2 UCSF Benioff Children's Hospital, San Francisco, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
5 University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, United States
6 Seattle Children's Hospital, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
7 University of California, San Francisco, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
8 Corewell Health Helen DeVos Children’s Hospital, Grand Rapids, Michigan, United States, Michigan State University College of Human Medicine, Grand Rapids, Michigan, United States
9 Columbia University School of Medicine, New York City, New York, United States
10 Arkansas Children's Research Institute, Little Rock, Arkansas, United States
11 UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
12 UCSF Benioff Children's Hospital, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States

Introduction: Burkitt leukemia/lymphoma (BL) is a rare, high-grade B-cell malignancy characterized by a hallmark MYC translocation, most commonly t(8;14) involving the IGH locus. Intensive chemotherapy is effective for the majority of pediatric patients at diagnosis, but outcomes for patients with relapsed/refractory (r/r) disease are dismal, with an overall survival (OS) rate of less than 30%. Considering nearly all BL cells express CD19, chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 is a rational therapeutic approach.

Methods: We conducted a nationwide retrospective study through the Pediatric Real-World CAR Consortium (PRWCC) of pediatric patients with BL treated with CD19-directed CAR-T therapy. Patients across eight institutions meeting eligibility of BL diagnosis and treatment with CAR-T therapy were included in the analysis. Complete response (CR) was defined as negative measurable residual disease by flow cytometry. Stringent event-free survival (EFS) was defined as time from infusion to r/r disease, loss of B-cell aplasia (BCA), or death. Categorical data were summarized as frequencies and percentages. Time-to-event data were analyzed with Kaplan-Meier estimates. Due to small sample size, results are descriptive in nature.

Results: Thirteen patients were included. Median age was 13.8 years at original diagnosis (range, 1.7–23.6). A MYC abnormality was documented in 11, including IGH::MYC/t(8;14) in 8. Patients received a median of 3 prior lines of therapy, and indication for CAR-T was either primary refractory disease (6) or relapse (7). Products were tisagenlecleucel (9), axicabtagene ciloleucel (1), and an investigational 4-1BB product (3). The most frequently used lymphodepletion regimen was fludarabine plus cyclophosphamide (11). Cytokine release syndrome (CRS) occurred in 11 (grade ≥3, 3) and immune cell-associated neurotoxicity syndrome (ICANS) in 3 (grade ≥3, 1). Six of 13 patients (46.2%) achieved CR as their best response, including 1/6 (16.7%) with primary refractory disease and 5/7 (71.4%) with relapsed disease. One patient with initial CR after CAR-T relapsed pre-HSCT. All five remaining patients with CAR-mediated CR underwent consolidative HSCT. Of these, 3/5 remain in CR, 1 relapsed and died, and 1 died of treatment-related mortality (veno-occlusive disease) while in remission. Among patients who did not achieve initial CR, 2/6 underwent HSCT after further salvage therapy, with 1/6 still in ongoing CR. Median time from CAR-T to HSCT was 1.7 months (range 1.6–5.6) for patients transplanted in CR versus 7.6 months (range 7.6–7.7) for the two transplanted after other salvage therapies.

Median duration of response and BCA among responders (CR + PR) was 4.4 months and 3.7 months (range 1.9–21.2), respectively. Median EFS was 2.6 months (95% CI, 0.9–5.3) and 24-month EFS was 9.2% (95% CI, 0.6–33.4). Median OS was 21.7 months (95% CI, 2.9–NR) and 24-month OS was 40.6% (95% CI, 13.8–66.3). At last follow-up, 5/13 patients were in continuous CR at data cut-off (22.6 months, range 2.9–31.9), with 8/13 having developed r/r disease and 6/13 patients alive. Among patients with documented immunophenotype at relapse/progression post CAR-T, 4 were CD19-positive and 3 were CD19-negative.

Compared with a non-overlapping pediatric B-ALL cohort previously reported from the PRWCC (Schultz et al., 2022), CAR-T-treated BL patients had lower CR rates (46.2% [95% CI, 23–71] vs. 85% [95% CI, 79–89]), and 12-month OS (59.2% [95% CI, 27.9–80.7] vs. 72%). Outcomes were similar to those recently reported (Samples et al., 2025) in adults with r/r Burkitt lymphoma treated with CD19 CAR-T, with a comparable CR rate (46.2% [95% CI, 23–71] vs. 41.9% [95% CI, 26–59]).

Conclusion: CAR-T therapy in pediatric patients with BL was associated with inferior outcomes compared to pediatric B-ALL, but comparable outcomes to adults with BL. Outcomes were worse for primary refractory disease compared to relapsed disease. Even among those achieving CR, BCA was short-lived. Best outcomes occurred when CAR-T responders were consolidated with HSCT. Overall, limitations of CAR-T therapy in pediatric BL include suboptimal CR rates, brief response duration, transient BCA, and potential for antigen escape associated with CD19-negative disease.

Farhaz Shaikh, BA: No relevant conflicts of interest to declare.